Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
36(12):2541-50
indicating that it is devoid of CCR5 agonist activity
Approved by the FDA in 2002
88 mumol/L on RET kinase
InChi: InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7
Trastuzumab deruxtecan othenic acid 36(12):2541-50Trastuzumab deruxtecan (DS 8201a) is an anti human epidermal growth factor receptor 2 (HER2) antibody drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti HER2 antibody, an enzymatically cleavable peptide linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2 positive breast cancer and gastric cancer. Product information CAS Number: 1826843 81 5 Molecular Weight: 493. 48 Formula: